Sun Pharma issues recall of IV muscle relaxant after glass fragments found

Sun Pharma sign
The recall includes three lots of 10 milligrams of lyophilized powder and one lot of 20 milligrams of lyophilized powder, both of which must be reconstituted before being administered. (Sun Pharma)

India’s Sun Pharmaceuticals has issued a voluntary recall of four lots of the muscle relaxant vecuronium bromide for injection after particulate matter identified as glass was found in the product.

The recall includes three lots of 10 milligrams of lyophilized powder and one lot of 20 milligrams of lyophilized powder, both of which must be reconstituted before being administered.

Sun said in the recall posted on the FDA’s website that the product was distributed nationwide in the U.S. to wholesale customers and medical facilities. It began notification of the recall earlier this month.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

To date, the company said, no adverse events related to the recall have been reported.

Vecuronium bromide, which is sold under the brand name Norcuron as well as other names, is used during general anesthesia to aid in intubation by relaxing skeletal muscles. 

Sun is currently under investigation by the Securities and Exchange Board of India for alleged insider trading claims related to the 2014 acquisition of its former rival Ranbaxy from Japan’s Daiichi Sankyo. According to reports, a whistleblower accused Sun of manipulating stock prices of its acquisition targets directly or indirectly.

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

Pfizer is pushing back on a Thursday report claiming it suddenly revised its COVID-19 vaccine targets for 2020, saying it announced that last month.